Actively Recruiting
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC
Led by University Hospital, Lille · Updated on 2022-03-15
100
Participants Needed
1
Research Sites
362 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current context of a shortage of transplants. Performing a PET CT scan is not currently recommended in the pre-liver transplant workup for HCC. However, PET CT using in a complementary manner the FDG and Choline tracers appears promising in the management of HCC in view of its wide use in oncology and its major diagnostic and prognostic contribution compared to conventional imaging. In order to address this issue, a prospective cohort study including patients from the University Hospital of Rouen and Lille with hepatocellular carcinoma meeting the criteria for indication of liver transplantation validated in SPC will be set up, the main objective of which will be to assess the decision-making contribution of PET TDM FDG and Choline in addition to conventional imaging in the pre-transplant assessment.
CONDITIONS
Official Title
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient candidate for liver transplantation for hepatocellular carcinoma from the University Hospital of Lille and Rouen, with transplantation project validated and AFP score 64 2
- Diagnosis of HCC defined by non-invasive imaging criteria per EASL-EORTC 2012 recommendations or confirmed histologically
- No opposition to participating in the study
- Patient affiliated to a social security scheme
You will not qualify if you...
- AFP score 63
- Contraindication to PET FDG or Choline
- Presence of other tumor such as cholangiocarcinoma
- Unbalanced diabetes with HbA1c > 9% and fasting hyperglycemia > 2g/L preventing PET completion
- Patient under guardianship or curatorship
- Pregnant or breastfeeding woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hop Claude Huriez Chu Lille
Lille, France, 59037
Actively Recruiting
Research Team
G
Guillaume Lassailly, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here